IMNM: Immunome Inc Price to Sales
Immunome, Inc. (IMNM) development of targeted antibodies remains independent of market cycles, as confirmed by the current P/S multiple. The value 741.00 establishes a new valuation benchmark. The business relies on partner payments prior to the market launch of oncology drugs. Risks are limited to standard biohazardous waste disposal controls, ensuring the company's baseline environmental compliance.
Immunome Corp (IMNM) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
IMNM - Net Profit|Expected Net Profit Immunome, Inc.|IMNM - Price to Earnings Ratio|Future Price to Earnings Multiple Immunome Inc|IMNM - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Immunome Corp|IMNM - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Immunome|IMNM - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months immunome.com|IMNM - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Immunome, Inc.
- total revenue and sales volume data:
Fundamental company analysis:immunome.com (IMNM)
The ratio of market capitalization to annual revenue determines the investment value per unit of turnover, reflecting the current market interpretation of the business's value. The P/S multiple dynamics for Immunome, Inc. (IMNM) allow for an assessment of the company's valuation adequacy relative to the pace of milestone achievements and the efficiency of its cash burn, which is critical for a biotech firm in the development phase of targeted conjugates.
Competitors of Immunome, Inc.
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Price-to-Revenue Coefficient Protagonist Corp PTGX|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|Market Cap to Revenue kiniksa.com|Price-to-Revenue Ratio Grifols|Market Cap to Revenue Adaptive Biotech (ADPT)|Market Cap to Revenue CLDX (Celldex)|P/S Multiple Aurinia Corp (AUPH)|Price-to-Revenue Ratio BioCryst BCRX|VERA: Market Cap to Revenue Ratio|DNTH - Price-to-Revenue Ratio|Price to Sales Pharvaris NV|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Market Cap to Revenue Tourmaline|PGEN (Precigen, Inc.) - P/S Multiple|Price to Sales pharming.com PHAR|Market Cap to Revenue NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Price-to-Revenue Coefficient Gossamer Bio Corp. (GOSS)|KALV - Price-to-Revenue Ratio|SEPN (septerna.com) - Market Cap to Revenue Ratio|PVLA: P/S Multiple|Market Cap to Revenue Savara Inc|Market Cap to Revenue RIGL|AnaptysBio Inc. (ANAB) - Price-to-Revenue Coefficient|P/S Multiple ATXS|Price-to-Revenue Coefficient engene.com|Price-to-Revenue Ratio RAPT Therapeutics RAPT|JBIO - Market Cap to Revenue|ACRS - Price-to-Revenue Ratio|KYTX (Kyverna Therapeutics, Inc) - Market Cap to Revenue Ratio|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|Market Cap to Revenue cabalettabio.com|Price-to-Revenue Ratio Ventyx Biosciences, Inc.|Theratechnologies, Inc. - Price-to-Sales Ratio|P/S Multiple AVTX|ELDN (Eledon Pharmaceuticals, Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple AGEN (Agenus)|P/S Multiple climbbio.com CLYM|ZURA - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ATYR (aTyr Pharma Inc)|adagene.com (ADAG) - Price-to-Revenue Ratio|Market Cap to Revenue Ikena Oncology|STTK (Shattuck Labs Inc) - P/S Multiple|P/S Multiple Equillium Bio|Market Cap to Revenue CNTB (Connect Biopharma)|IMUX (immunic-therapeutics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ATRA (Atara Bio)|Price-to-Revenue Coefficient InflaRx NV (IFRX)|XFOR - Price-to-Revenue Ratio|Adicet Bio (ACET) - Market Cap to Revenue|celularity.com (CELU) - Price-to-Revenue Ratio|Market Cap to Revenue INmune Bio Inc|Market Cap to Revenue BRNS|P/S Multiple Kezar Life Sciences Inc|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|akaritx.com - Market Cap to Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Q32 Bio Inc (QTTB) - Price to Sales|GeoVax Labs Inc - P/S Multiple|Price-to-Revenue Coefficient Edesa Biotech Corp EDSA|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Carisma Therapeutics Inc.|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Bolt Bio (BOLT)|Market Cap to Revenue HCWB (HCW Biologics Inc.)|P/S Multiple aptevotherapeutics.com (APVO)|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX: Market Cap to Revenue Ratio|GRI - Price-to-Revenue Ratio|Price to Sales XORTX Therapeutics Inc|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Market Cap to Revenue Revelation Biosciences Corp|INDP (Indaptus Therapeutics) - P/S Multiple|Price to Sales scinai.com SCNI|Market Cap to Revenue CALI (CalciMedica, Inc.)|AFMD (affimed.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos)|Price-to-Revenue Coefficient HOOKIPA Pharma, Inc. (HOOK)|IGMS - Price-to-Revenue Ratio|ITOS (iteostherapeutics.com) - Market Cap to Revenue Ratio|OCEA: P/S Multiple|Market Cap to Revenue TC BioPharm (Holdings) Plc|Market Cap to Revenue THRD
